Evaluation of Full Blood Count in Patients With Cushings Syndrome Attending Federal Teaching Hospital, Owerri, Nigeria.
DOI:
https://doi.org/10.37506/b7a35970Keywords:
Cushing’s Syndrome, Full Blood Count, Cortisol, OwerriAbstract
Cushing’s syndrome is a hormonal disorder caused by prolonged exposure to high cortisol levels, either produced naturally by the body or introduced through steroid medications. While its effects on metabolism and hormonal balance are well known, it can also lead to significant changes in blood parameters. This study was carried out to investigate those haematological changes in patients with Cushing’s syndrome in Owerri, Imo State, Nigeria, with the goal of improving clinical understanding and patient care at the Federal Teaching Hospital, Owerri.
A total of 30 patients diagnosed with Cushing’s syndrome were compared with 30 healthy individuals of similar age and sex. Blood samples were collected and analyzed for red blood cell indices, white cell counts, and platelet levels. The data was processed using SPSS version 27. Results showed that patients with Cushing’s syndrome had lower levels of haemoglobin (8.64 ± 1.63 g/dL), packed cell volume (25.53 ± 4.88%), red blood cell count (3.28±0.68 × 10¹²/L), mean cell volume (74.63 ± 11.29 fL), mean cell haemoglobin (25.93 ± 3.15 pg), and lymphocyte percentage (28.30±10.99%) compared to the control group. In contrast, red cell distribution width (15.70 ± 2.29%), total white blood cell count (10.55 ± 4.04 × 109/L), neutrophils (66.23 ± 12.93%), and platelets (310.10 ± 108.33 × 109/L) were significantly higher in the Cushing’s group. When haematological parameters were compared between patients aged 20-40 years and those above 40 years, no significant differences were found, indicating that age did not appear to significantly influence the blood profile in this cohort.No significant differences were also observed among males and females with cushing’ssyndrome.Mean cell volume showed a non-significant positive relationship with PCV, haemoglobin, RBC, MCH, MCHC, and neutrophils, and a non-significant negative relationship with RDW, white blood cells, lymphocytes, monocytes, eosinophils, and platelets.
References
Nieman LK, Biller BM, Findling JW, Murad MH, Newell-
Price J, Savage MO, et al. The diagnosis of Cushing’s
syndrome: An Endocrine Society Clinical Practice
Guideline. J Clin Endocrinol Metab. 2008;93(5):1526–
Pivonello R, Isidori AM, De Martino MC, Newell-
Price J, Biller BM, Colao A. Complications of Cushing’s
syndrome: state of the art. Lancet Diabetes Endocrinol.
;4(7):611–629.
Sharma ST, Nieman LK. Cushing’s syndrome: all
variants, detection, and treatment. Endocrinol Metab
Clin North Am. 2011;40(2):379–391.
Newell-Price J, Bertagna X, Grossman AB, Nieman LK.
Cushing’s syndrome. Lancet. 2006;367(9522):1605–1617.
Fardet L, Petersen I, Nazareth I. Risk of infections
associated with oral glucocorticoid use in patients with
chronic inflammatory diseases: a population-based
cohort study. JAMA Intern Med. 2016;176(7):1014–1023.
Anagnostis P, Athyros VG, Tziomalos K, Karagiannis
A, Mikhailidis DP. Clinical review: The pathogenetic
role of cortisol in the metabolic syndrome: a hypothesis.
J Clin Endocrinol Metab. 2009;94(8):2692–2701.
Newell-Price J, Bertagna X, Grossman AB, Nieman LK.
Cushing’s syndrome. Lancet. 2006;367(9522):1605–17.
Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini
F, Chrousos GP, et al. Diagnosis and complications
of Cushing’s syndrome: a consensus statement. J Clin
Endocrinol Metab. 2003;88(12):5593–602.
Sharma ST, Nieman LK, Feelders RA. Cushing’s
syndrome: epidemiology and developments in disease
management. Clin Epidemiol. 2015;7:281–93.
Valassi E, Franz H, Zacharieva S, Santos A, Albarel
F, Biller BMK, et al. Prevalence and complications of
Cushing’s syndrome in a contemporary population.
Clin Endocrinol (Oxf). 2011;75(4):458–64.
Raff H, Carroll T. Cushing’s syndrome: from
physiological principles to diagnosis and clinical care.
J Physiol. 2015;593(3):493–506.
Buttgereit F, Burmester GR, Brand MD. Bioenergetics
of immune functions: fundamental and therapeutic
aspects. Immunol Today. 2000;21(4):192–9.
Dhabhar FS. Enhancing versus suppressive
effects of stress on immune function: implications
for immunoprotection and immunopathology.
Neuroimmunomodulation. 2009;16(5):300–17.
Schimmer BP, Parker KL. Adrenocorticotropic hormone;
adrenocortical steroids and their synthetic analogs;
inhibitors of the synthesis and actions of adrenocortical
hormones. In: Brunton LL, Chabner BA, Knollmann BC,
editors. Goodman and Gilman’s: The Pharmacological Basis
of Therapeutics. 12th ed. New York: McGraw-Hill; 2011.
Sibal L, Reid C, Ingle L, Rajput A, Greenwood R, Mark P.
Haematological abnormalities in Cushing’s syndrome.
Clin Endocrinol (Oxf). 2006;64(2):156–62.
Arafah BM, Nishiyama FJ, Tlaygeh H, Hejal R.
Measurement of serum free cortisol in critically ill
patients. N Engl J Med. 2007;357(8):837–41.
Arnaldi G, Mancini T, Tirabassi G, Boscaro M. Advances
in the epidemiology, pathogenesis, and management of
Cushing’s syndrome complications. J Endocrinol Invest.
;28(11):983–91.
Van der Pas R, Leebeek FW, Hofland LJ, de Herder
WW, Feelders RA. Hypercoagulability in Cushing’s
syndrome: prevalence, pathogenesis and treatment.
Clin Endocrinol (Oxf). 2013;78(4):481–8.
Kumari N, Raina SK, Bhardwaj P, Bansal A.
Hematological alterations in Cushing’s syndrome:
A case-control study. Indian J Endocrinol Metab.
;25(1):45–9.
Choudhury M, Sharma S, Mehta A. Correlation of red
blood cell indices and white cell count in patients with
endogenous Cushing’s syndrome. J Clin Diagn Res.
;13(4):BC01–BC04.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.